We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.94B
AUM Growth
-$224M
Cap. Flow
-$1.92B
Cap. Flow %
-24.14%
Top 10 Hldgs %
74.98%
Holding
115
New
11
Increased
21
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$30.4M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$19.4M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$16.5M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$15.8M
5
XNPT
XENOPORT, INC.
XNPT
+$13.6M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$209M
2
QCOR
QUESTCOR PHARMA INC
QCOR
+$46.2M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$32.8M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 39.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
76
Aurinia Pharmaceuticals
AUPH
$1.95B
$2.34M 0.03%
+727,669
New +$2.59M
ALDR
77
DELISTED
Alder Biopharmaceuticals
ALDR
$1.94M 0.02%
153,350
– –
OSUR icon
78
OraSure Technologies
OSUR
$273M
$1.69M 0.02%
234,664
– –
SVRA icon
79
Savara
SVRA
$1.08B
$1.67M 0.02%
+42,857
New +$1.8M
MDGL icon
80
Madrigal Pharmaceuticals
MDGL
$12.6B
$1.5M 0.02%
14,286
– –
RCPT
81
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$1.48M 0.02%
23,900
– –
FMI
82
DELISTED
Foundation Medicine, Inc.
FMI
$1.48M 0.02%
78,162
– –
ISEE
83
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.43M 0.02%
36,776
– –
MDWD icon
84
MediWound
MDWD
$184M
$1.42M 0.02%
32,143
– –
SLXP
85
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$1.35M 0.02%
8,621
-125,100
-94% -$18.1M
MRNS
86
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.32M 0.02%
+51,119
New +$1.58M
LOXO
87
DELISTED
Loxo Oncology, Inc
LOXO
$1.31M 0.02%
+100,000
New +$1.3M
RIGL icon
88
Rigel Pharmaceuticals
RIGL
$723M
$935K 0.01%
48,197
– –
ALNY icon
89
Alnylam Pharmaceuticals
ALNY
$38.3B
$906K 0.01%
11,600
– –
AKAO
90
DELISTED
Achaogen Inc
AKAO
$896K 0.01%
100,000
– –
XLRN
91
DELISTED
Acceleron Pharma
XLRN
$870K 0.01%
28,765
– –
TSRO
92
DELISTED
TESARO, Inc.
TSRO
$840K 0.01%
31,218
– –
GERN icon
93
Geron
GERN
$898M
$805K 0.01%
402,629
-23,352
-5% -$57.6K
TCRT icon
94
Alaunos Therapeutics
TCRT
$4.64M
$646K 0.01%
1,631
– –
QURE icon
95
uniQure
QURE
$2.75B
$284K ﹤0.01%
30,672
– –
FPRX
96
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$233K ﹤0.01%
19,823
– –
CCXI
97
DELISTED
ChemoCentryx, Inc.
CCXI
$225K ﹤0.01%
50,000
– –
GALT icon
98
Galectin Therapeutics
GALT
$230M
– –
-300,000
Closed -$4.14M
CLVS
99
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-793,221
Closed -$32.8M
AEGR
100
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-413,922
Closed -$13.3M
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Baker Bros. Advisors held 115 positions worth $7.94B, down 2.7% from $8.16B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $1.92B in Q3 2014, closing 7 positions and reducing 12 holdings. Its most notable exit was INTERMUNE INC, an estimated $209M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 40% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $18.2M.

  • Baker Bros. Advisors's largest Q3 2014 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 201,856 shares worth $18.2M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q3 2014, an estimated $30.4M increase.
  • Baker Bros. Advisors's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $18.1M.
  • Baker Bros. Advisors fully exited INTERMUNE INC in Q3 2014, selling an estimated $209M.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $7.94B portfolio in Q3 2014.
  • Baker Bros. Advisors opened 11 new positions and closed 7 in Q3 2014.
  • Baker Bros. Advisors's portfolio value fell 2.7% quarter-over-quarter to $7.94B.

Based on Baker Bros. Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.